epitalon or epithalon peptide scientific studies clinical trials khavinson – Foundry Epithalon — Research Peptide Information – epitalon or epithalon scientific studies

Secondary effects from IGF-1 therapy were reported after administration of doses higher than 6080 g/kg/day

The key findings from this clinical program include significant reductions in body weight and fat mass in treatment groups compared to placebo, preferential loss of abdominal and visceral adipose tissue, no changes in serum IGF-1 levels at any dose tested, no negative effects on glucose metabolism or insulin sensitivity, no significant adverse events related to metabolic or endocrine disruption, and safety profile indistinguishable from placebo for most parameters

Given BPC-157's angiogenic properties (VEGF upregulation), theoretical concern exists about promoting vascular growth in hepatocellular carcinoma, though no case reports have documented this outcome [1]

A retinoid for skin